About: SARS-CoV-2 neutralizing antibody levels are correlated with severity of COVID-19 pneumonia

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: SARS-CoV-2 neutralizing antibody levels are correlated with severity of COVID-19 pneumonia Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	SARS-CoV-2 neutralizing antibody levels are correlated with severity of COVID-19 pneumonia
Creator	Wang, Xu Wang, Lin-Fa Chen, Wei Yi, Yongxiang Zhang, Yongchen Zhang, Jie Hu, Zhiliang Liu, Xuan Yi, Changhua Xu, Chuanjun Liu, Pei Zhang, Libo Qin, Xijian Tang, Shuangshuang Wang, Weixiao Xu, Miaomiao
source	Elsevier; PMC
abstract	Abstract The emerging coronavirus disease 2019 (COVID-19) has become a serious global public health threat. With more and more recovered patients, it is urgently needed for evaluation of the neutralizing antibody (NAb) in these patients. In this study, we collected blood samples from 49 patients recently recovered from COVID-19. Serum NAbs were measured using a novel surrogate virus neutralization test (sVNT). Factors associated with NAb titers were analyzed using Ordinary Least Squares regression model. The median age of the study participants was 37 years (IQR, 30.0-54.5) and 55.1% (27/49) of which were male. The median time to blood collection (for NAb analysis) from illness onset, viral clearance and discharge were 43.0 days (IQR, 36.0-50.0), 27.0 days (IQR, 20.5-37) and 17.0 days (IQR, 15.0-33.0), respectively. Patients had a median NAb titer of 1: 40 (IQR, 1:15-1:120). NAbs were not detected in two asymptomatic children who quickly cleared the virus. NAb titers were higher in patients with older age (p = 0.020), symptomatic infection (p = 0.044), more profound lung involvement (p＜0.001), abnormal C-reactive protein level (p＜0.01) and elevated lactate dehydrogenase (p = 0.019). Multivariable analysis revealed that severity of pneumonia and having comorbidity positively correlated with NAb titers in recovered patients (p = 0.02), while use of corticosteroids negatively impacted NAb titers (p = 0.01). Our study suggests that some COVID-19 patients may not have detectable NAb after recovery. SARS-CoV-2 NAb titers are positively correlated with severity of COVID-19 pneumonia.
has issue date	2020-08-13(xsd:dateTime)
bibo:doi	10.1016/j.biopha.2020.110629
has license	els-covid
sha1sum (hex)	8096fc6fd9e9a7fc53e135fa751e53329e70642d
schema:url	https://doi.org/10.1016/j.biopha.2020.110629
resource representing a document's title	SARS-CoV-2 neutralizing antibody levels are correlated with severity of COVID-19 pneumonia
has PubMed Central identifier	PMC7425713
schema:publication	Biomedicine & Pharmacotherapy
resource representing a document's body	covid:8096fc6fd9e9a7fc53e135fa751e53329e70642d#body_text
is schema:about of	named entity 'Biomedicine' named entity 'neutralizing antibody' named entity 'SARS-CoV-2' named entity 'neutralizing antibody' named entity 'neutralizing antibody' named entity 'levels' named entity 'Pharmacotherapy' named entity 'amp' named entity 'Journal' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'pneumonia' named entity 'doi' named entity 'pneumonia' named entity 'pneumonia' named entity 'COVID-19' named entity 'Nanjing' named entity 'COVID' named entity 'COVID' named entity 'NAb' named entity 'viruses' named entity 'infection' named entity 'immune cells' named entity 'corticosteroid' named entity 'erythrocyte sedimentation rate' named entity 'ethics committee' named entity 'D-dimer' named entity 'intravenous immunoglobulin' named entity 'neutralization test' named entity 'multivariate analyses' named entity 'serum samples' named entity 'C-reactive protein' named entity 'chest CT' named entity 'NAb' named entity 'antibody' named entity 'SPSS' named entity 'correlation' named entity 'NAb' named entity 'positive correlation' named entity 'renal function' named entity 'neutralization test' named entity 'pneumonia' named entity 'COVID' named entity 'pneumonia' named entity 'COVID-19' named entity 'NAb' named entity 'COVID-19' named entity 'comorbidity' named entity 'lymphocyte count' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'herd immunity' named entity 'follow-up' named entity 'SARS-CoV-2' named entity 'Fisher's exact test' named entity 'statistically significant' named entity 'NAb' named entity 'SARS-CoV-2' named entity 'LDH' named entity 'antibody' named entity 'asymptomatic infection' named entity 'life-threatening' named entity 'computed tomography' named entity 'COVID' named entity 'TMB' named entity 'titer' named entity 'throat swab' named entity 'lactate dehydrogenase' named entity 'SARS-CoV-2'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software